{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T22:34:21Z","timestamp":1696372461618},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T00:00:00Z","timestamp":1393977600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0090462","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T21:32:05Z","timestamp":1394055125000},"page":"e90462","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Donor and Recipient Single Nucleotide Polymorphisms of IL28B rs8099917 in Living Donor Liver Transplantation for Hepatitis C"],"prefix":"10.1371","volume":"9","author":[{"given":"Nobuhiro","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumihito","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyo","family":"Yamashiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Kokudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,3,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"GM Lauer","year":"2001","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2893.2008.01012.x","article-title":"Expert opinion on the treatment of patients with chronic hepatitis C","volume":"16","author":"S Zeuzem","year":"2009","journal-title":"J Viral Hepat"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature04083","article-title":"Hepatitis C and liver transplantation","volume":"436","author":"RS Brown","year":"2005","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0168-8278(01)00179-9","article-title":"Hepatitis C and liver transplantation","volume":"35","author":"M Berenguer","year":"2001","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/lt.20572","article-title":"Kinetics of hepatitis C virus reinfection after liver transplantation","volume":"12","author":"KA Powers","year":"2006","journal-title":"Liver Transpl"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation","volume":"35","author":"M Garcia-Retortillo","year":"2002","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"M Berenguer","year":"2000","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/lt.21117","article-title":"A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation","volume":"13","author":"N Yilmaz","year":"2007","journal-title":"Liver Transpl"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"LM Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/lt.21123","article-title":"Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States","volume":"13","author":"PJ Thuluvath","year":"2007","journal-title":"Liver Transpl"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/lt.20865","article-title":"Treating hepatitis C infection in liver transplant recipients","volume":"12","author":"NA Terrault","year":"2006","journal-title":"Liver Transpl"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/lt.20737","article-title":"Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C","volume":"12","author":"M Berenguer","year":"2006","journal-title":"Liver Transpl"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-6143.2006.01619.x","article-title":"Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection post transplantation","volume":"7","author":"T Bizollon","year":"2007","journal-title":"Am J Transplant"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"6","author":"CS Wang","year":"2006","journal-title":"Am J Transplant"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"JA Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00534-007-1295-5","article-title":"Treatment strategy for hepatitis C after liver transplantation","volume":"15","author":"S Tamura","year":"2008","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/01.TP.0000142677.12473.E5","article-title":"Preemptive therapy for hepatitis C virus after living-donor liver transplantation","volume":"78","author":"Y Sugawara","year":"2004","journal-title":"Transplantation"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1432-2277.2009.01023.x","article-title":"Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience","volume":"23","author":"S Tamura","year":"2010","journal-title":"Transpl Int"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"D Ge","year":"2009","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Y Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"V Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1053\/j.gastro.2010.07.058","article-title":"Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C","volume":"139","author":"T Fukuhara","year":"2010","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/j.1440-1746.2012.07129.x","article-title":"Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon\/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation","volume":"27","author":"T Kawaoka","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199601113340203","article-title":"Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection","volume":"334","author":"N Enomoto","year":"1996","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000086064","article-title":"Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy","volume":"48","author":"N Akuta","year":"2005","journal-title":"Intervirology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","article-title":"Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C","volume":"139","author":"M Honda","year":"2010","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","article-title":"Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C","volume":"140","author":"MT Dill","year":"2011","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2011.01.050","article-title":"IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C","volume":"55","author":"PY Bochud","year":"2011","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.24074","article-title":"Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection","volume":"53","author":"MR Charlton","year":"2011","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/TP.0b013e3182547551","article-title":"The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables","volume":"94","author":"A Duarte-Rojo","year":"2012","journal-title":"Transplantation"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2010.10.037","article-title":"Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection","volume":"55","author":"CM Lange","year":"2011","journal-title":"J Hepatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/lt.22235","article-title":"Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation","volume":"17","author":"D Eurich","year":"2011","journal-title":"Liver Transpl"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00535-012-0680-2","article-title":"Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation","volume":"48","author":"G Crespo","year":"2013","journal-title":"J Gastroenterol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1600-6143.2011.03491.x","article-title":"Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation","volume":"11","author":"M Coto-Llerena","year":"2011","journal-title":"Am J Transplant"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"AJ Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jmv.22272","article-title":"Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b","volume":"84","author":"H Toyoda","year":"2012","journal-title":"J Med Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"KE Sherman","year":"2012","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2012.07.035","article-title":"New therapies against HCV: expected risks and challenges associated with their use in the liver transplant setting","volume":"57","author":"GW McCaughan","year":"2012","journal-title":"J Hepatol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0090462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T15:31:22Z","timestamp":1540308682000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0090462"}},"subtitle":[],"editor":[{"given":"John E.","family":"Tavis","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,5]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0090462","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,5]]}}}